News & Events

AGC Biologics fosters strong customer partnerships by conducting virtual meetings

Tokyo, March 17, 2020 – AGC Inc., (Headquarters: Tokyo; President & CEO: Takuya Shimamura) has decided to launch a voluntary tender offer (“VTO”) to acquire all ordinary shares of Molecular Medicine S.p.A. (“Molmed”) a company with shares listed on the Italian Stock Exchange (Milan) pursuant to article 102, first paragraph, of the Italy Legislative Decree No. 58 of 24 February 1998 and related regulations. Molmed is a clinical stage biotechnology company focused on research, development, manufacturing and clinical validation of gene & cell therapies, and offers GMP services for the development and manufacturing of gene & cell therapies for third parties and/or in partnership at its authorized facilities (“CDMO Services”^*1).